Landscape review of global real-world data sources for studying medication use in pregnancy and lactation that support regulatory decision making.
breastfeeding
mother-infant
pharmacoepidemiology
pregnancy
real-world data
Journal
Pharmacoepidemiology and drug safety
ISSN: 1099-1557
Titre abrégé: Pharmacoepidemiol Drug Saf
Pays: England
ID NLM: 9208369
Informations de publication
Date de publication:
18 Oct 2023
18 Oct 2023
Historique:
revised:
11
09
2023
received:
20
03
2023
accepted:
26
09
2023
medline:
18
10
2023
pubmed:
18
10
2023
entrez:
18
10
2023
Statut:
aheadofprint
Résumé
Most pregnant people take at least one medication during gestation or while breastfeeding, however data are lacking on the safety of medication use in these populations. We conducted a landscape review of real-world data sources specific to medication use in pregnancy and breastfeeding populations that have met, or have potential to meet, health authorities' requirements for post-authorization safety studies. A 2-phase approach identified data sources from literature, publicly available registers of non-interventional post-authorization studies of pregnant women, existing database inventories, and emerging data sources known to the authors. Required key attributes were assessed according to current regulatory guidance, resulting in selection of 49 suitable data sources. All global regions were represented, with North America (37%) and Europe (33%) most common; 12% of the data sources included pregnancy information from low-to middle-income countries. Administrative healthcare claims (25%) and electronic healthcare records (21%) comprised the largest types of data sources. Across data sources, 53% were managed by national or regional governments, 27% by industry, and 20% by academic institutions. Maternal age, diagnoses, prenatal care, and reproductive history were available in most, whereas fewer included demographic data (e.g., race/ethnicity). Breastfeeding data were collected in 37% of the final data sources. We conducted a systematic approach to data source evaluation of pregnancy and breastfeeding to be used as a resource for investigators to consider when designing pregnancy-related research studies to satisfy regulatory requirements.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd.
Références
Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernández-Díaz S. National Birth Defects Prevention Study. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol. 2011;205(1):51.e1-51.e518. doi:10.1016/j.ajog.2011.02.029
Lupattelli A, Spigset O, Twigg MJ, et al. Medication use in pregnancy: a cross-sectional, multinational web-based study. BMJ Open. 2014;4:e004365. doi:10.1136/bmjopen-2013-004365
McClatchey AK, Shield A, Cheong LH, Ferguson SL, Cooper GM, Kyle GJ. Why does the need for medication become a barrier to breastfeeding? A Narrative Review Women Birth. 2018 31:362-366.
US Food and Drug Administration. Content and format of labeling for human prescription drug and biological products: requirements for pregnancy and lactation labeling. Fed Regist. 2014;79(233):72063-72103.
Byrne JJ, Saucedo AM, Spong CY. Evaluation of drug labels following the 2015 pregnancy and lactation labeling rule. JAMA Netw Open. 2020;3(8):e2015094. doi:10.1001/jamanetworkopen.2020.15094
Ghalandari N, Dolhain RJEM, Hazes JMW, et al. The pre- and post-authorisation data published by the European medicines agency on the use of biologics during pregnancy and lactation. Br J Clin Pharmacol. 2020;86(3):580-590.
Chappell LC, Tong S. Improving knowledge on safety is key to enabling drug access for pregnant and breastfeeding women. Clin Pharmacol Ther. 2021;110(4):866-868. doi:10.1002/cpt.2325
European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) - product- or population-specific considerations III: pregnant and breastfeeding women. Chapter P.III EMA/653036/2019. Published 4 December 2019. Accessed January 27, 2023, https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-product-population-specific-considerations-iii_en.pdf
US Food and Drug Administration. Postapproval pregnancy safety studies - draft guidance for industry. Published May 2019. Accessed December 13, 2022, https://www.fda.gov/media/124746/download
Nooney J, Thor S, de Vries C, et al. Assuring access to safe medicines in pregnancy and breastfeeding. Clin Pharmacol Ther. 2021;110(4):941-945. doi:10.1002/cpt.2212
US Food and Drug Administration. Real-world data: assessing registries to support regulatory decision-making for drug and biological products - draft guidance for industry. Published November 2021. Accessed December 13, 2022, https://www.fda.gov/media/154449/download
US Food and Drug Administration. Real-world data: assessing electronic health records and medical claims data to support regulatory decision-making for drug and biological products - draft guidance for industry. Published September 2021. Accessed December 13, 2022, www.fda.gov/media/152503/download
Krastein J, Sahin L, Yao L. A review of pregnancy and lactation postmarketing studies required by the FDA. Pharmacoepidemiol Drug Saf. 2022;32:287-297.
ISPE Guidelines for Good Pharmacoepidemiology Practices (GPP). Accessed February 20, 2023, https://www.pharmacoepi.org/resources/policies/guidelines-08027/
World Bank. Data: World Bank country and lending groups. Accessed December 13, 2022, https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups
US Food and Drug Administration. Clinical lactation studies: considerations for study design. Published May 2019. Accessed December XX, 2022, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-lactation-studies-considerations-study-design
The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Annex 2 to the guide on methodological standards in pharmacoepidemiology. Available at https://www.encepp.eu/standards_and_guidances/methodologicalGuide.shtml
Innovative Medicines Initiative. ConcePTION. Accessed January 27, 2023, https://www.imi.europa.eu/projects-results/project-factsheets/conception
US Food and Drug Administration. Pregnant? Breastfeeding? FDA aims to improve drug information. Published December 2021. Accessed December 13, 2022, https://www.fda.gov/consumers/consumer-updates/pregnant-breastfeeding-fda-aims-improve-drug-information
PRGLAC report to the HHS secretary and congress from the task force on research specific to pregnant women and lactating women (PRGLAC). National Institutes of Health September 2018. Accessed January 27, 2023. https://www.nichd.nih.gov/sites/default/files/2018-09/PRGLAC_Report.pdf
Gkori M, Morris J, on behalf of the EUROmediSAFE consortium. EUROmediSAFE inventory: inventory of available data sources in all 28 EU member states for potential use when evaluating the long-term risks for children associated with in-utero exposure. July 2018 (Version 2). Accessed January 27, 2023. https://euromedicat.eu/content/EUROmediSAFE%20Inventory_Finalv2_2018_07_06.pdf
Ren Z, Bremer AA, Pawlyk AC. Drug development research in pregnant and lactating women. Am J Obstet Gynecol. 2021;225(1):33-42.
Huybrechts KF, Bateman BT, Hernández-Díaz S. Use of real-world evidence from healthcare utilization data to evaluate drug safety during pregnancy. Pharmacoepidemiol Drug Saf. 2019;28:906-922.